Employers have been talking about low-value care for years, but they’re trying to identify to remove the use of those services, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.
Employers have been talking about low-value care for years, but they’re trying to identify to remove the use of those services, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.
Transcript
How are employers trying to identify and remove low-value care services?
We talk about low-value care, we’ve been talking about low-value care for a lot of years, what we’re finding is that there continues to be a lot of inappropriate use or low-value care reimbursed under the plans. Sometimes I think we’re trying to attack it through a plan design standpoint. Recently, for example, we’ve identified that low-value medications are often being covered on a formulary. I think what we’re envisioning, and we are advocating for, is that’s often being done for other reasons than to provide the best care to employees, and so we’re attacking it from that standpoint.
Also, educational. There’s a lot of efforts through education through things like Choosing Wisely, to help people understand what their choices are and when is care appropriate. In addition, I think there is a general move to higher quality providers who do a better job of screening for appropriateness. And some of the centers of excellence programs that have been put in place have demonstrated some of their best value, in part, by providing the best care when it’s needed and not providing the care when it’s not.
Bird Flu Risks, Myths, and Prevention Strategies: A Conversation With the NFID's Dr Robert Hopkins
January 21st 2025Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.
Listen
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More